Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lymphoma / Leukemia / Myeloma News

Clinical Trial May Lead To More Effective Treatment For Blood Cancers

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Blood / Hematology;  Cancer / Oncology
Article Date: 15 Jan 2009 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions
Current Article Ratings:

Patient / Public:4 stars

3.67 (3 votes)

Health Professional:2 and a half stars

2.33 (3 votes)

Article Opinions: 0 posts

Researchers with the Indiana University Melvin and Bren Simon Cancer Center want to find a way to speed up the growth of new cells following umbilical cord blood transplants in adult patients with blood cancers.

The researchers seek adult patients who have had an umbilical cord blood transplant to enroll in a phase II clinical trial to determine ways to make the treatment more effective.

Umbilical cord blood transplantation is an alternative source of stem cells for patients who lack an available matching donor for a bone marrow stem cell transplant. For adults, who need more stem cells than children, the umbilical cord transplant poses a problem because of the number of cells available from umbilical cord donations. The smaller number of cells affects the speed of the engraftment, the process in which the donated cells from a transplant start to grow and make new blood cells. This limits the effectiveness of umbilical cord transplants in adults.

Sherif Farag, M.B.B.S., Ph.D., associate professor of medicine and director of the Hematological Malignancies Program, who leads the study, hope that by blocking a stem cell protein, known as CD26, engraftment will take place faster.

Results from this trial may offer patients with blood cancers safer and more readily available treatments.

This clinical trial builds on previous groundbreaking studies by Hal Broxmeyer, Ph.D., chair and the Mary Margaret Walther Professor of Microbiology and Immunology at the IU School of Medicine and a researcher at the IU Simon Cancer Center. Dr. Broxmeyer found in the laboratory that inhibiting the protein CD26 enhances engraftment of low numbers of stem cells in animals.

The study is funded by the V Foundation for Cancer Research and the Signature Center Initiative at Indiana University - Purdue University Indianapolis.

Indiana University - Purdue University Indianapolis


Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Forum Icon

Lymphoma Forum

Discuss issues relating to lymphoma / leukemia / myeloma in our new forum.

Visit the lymphoma forum


These are the most read articles from this news category for the last 6 months:
Top Article Star
Allos Therapeutics' FOLOTYN™ First And Only FDA-Approved Therapy For Relapsed Or Refractory Peripheral T-cell Lymphoma
28 Sep 2009
Allos Therapeutics, Inc. (Nasdaq:ALTH) announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of...


CML Therapy Side Effects image CML Therapy Side Effects

Even "targeted" therapy for chronic myeloid leukemia is not without side effects. Some, like low blood counts, are serious. Hear how one patient, along with her oncologist, Dr. Neil Shah of UCLA, managed the side effects of her CML treatment...

Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

View more videos...